Table 3 Detailed subgroup analysis of clinicopathological parameters

Age > 50 vs. ≤ 50 (OR)

0.873 [0.761,1.002];

I2 = 0.0%; z = 1.93;

p = 0.054

0.868 [0.754,1.000];

I2 = 0.0%; z = 1.96;

p = 0.049

0.990 [0.513,1.912];

z = 0.03;

p = 0.976

_

0.869 [0.753,1.002];

I2 = 0.0%; z = 1.93;

p = 0.054

0.935 [0.563, 1.554];

I2 = 0.0%; z = 0.26;

p = 0.795

pT:T3/T4 vs. T1/T2 (OR)

0.646 [0.542,0.771]; I2 = 0.0%%; z = 4.85;

p < 0.001

0.661 [0.546,0.800];

I2 = 0.0%; z = 4.25;

p < 0.001

0.516 [0.297,0.898];

I2 = 0.0%; z = 2.34;

p = 0.019

0.695 [0.294,1.643]; z = 0.83;

p = 0.407

0.663 [0.550,0.798]; I2 = 0.0%; z = 4.33;

p < 0.001

0.516 [0.297, 0.898];

I2 = 0.0%; z = 2.34;

p = 0.019

LN(+) vs. LN(−)(OR)

0.941 [0.681,1.298]; I2 = 76.4%; z = 0.37;

p = 0.709

0.991 [0.633,1.551]; I2 = 80.8%; z = 0.04;

p = 0.968

1.013 [0.595,1.726]; I2 = 60.8%; z = 0.05;

p = 0.962

0.549 [0.322,0.936]; z = 2.20;

p = 0.028

1.003 [0.651,1.546]; I2 = 82.4%; z = 0.01;

p = 0.989

0.858 [0.501,1.468]; I2 = 66.5%; z = 0.56;

p = 0.576

IDC vs. ILC(OR)

2.654 [1.132,6.223]; I2 = 68.0%; z = 2.24;

p = 0.025

2.642 [0.700,9.967]; I2 = 84.0%; z = 1.43;

p = 0.152

2.883 [0.766,10.85]; I2 = 0.0%; z = 1.57;

p = 0.118

2.571 [0.614,10.77]; z = 1.29;

p = 0.196

4.735 [2.850,7.867]; I2 = 0.0%; z = 6.00;

p < 0.001

1.101 [0.622,1.951]; I2 = 0.0%; z = 0.33;

p = 0.740

Histological grade:III

vs.I–II(OR)

2.889 [2.218,3.762];

I2 = 49.5%; z = 7.87;

p < 0.001

2.871 [2.290,3.600]; I2 = 25.5%; z = 9.14;

p < 0.001

5.636 [3.050,10.42]; I2 = 0.0%; z = 5.52;

p < 0.001

1.659 [0.982,2.804]; z = 1.89;

p = 0.059

2.763 [2.188,3.489];

I2 = 39.7%; z = 8.53;

p < 0.001

3.284 [1.359,7.934];

I2 = 64.0%; z = 2.64;

p = 0.008

ER (+) vs.(−) (OR)

0.291 [0.185,0.458]; I2 = 70.0%; z = 5.35;

p < 0.001

0.348 [0.197,0.614]; I2 = 61.1%; z = 3.65;

p < 0.001

0.154 [0.090,0.264];

z = 6.80;

p < 0.001

0.342 [0.216,0.540]; z = 4.60;

p < 0.001

0.360 [0.230,0.563]; I2 = 60.1%;z = 4.49; p < 0.001

0.191 [0.105,0.346]; I2 = 30.4%; z = 5.44;

p < 0.001

PR (+) vs.(−) (OR)

0.396 [0.173,0.906];

I2 = 0.0%; z = 2.19;

p = 0.028

_

_

_

_

_

HER2 (+) vs.(−) (OR)

1.359 [0.646,2.858]; I2 = 88.0%; z = 0.81;

p = 0.419

1.443 [0.529,3.933]; I2 = 92.0%; z = 0.72;

p = 0.474

1.097 [0.539,2.230];

z = 0.25;

p = 0.799

_

1.871 [0.486,7.205];

I2 = 95.9%;z = 0.91; p = 0.362

0.961 [0.544, 1.699];

I2 = 0.0%; z = 0.14;

p = 0.891

Ki-67: high vs. low

6.378 [3.674,11.073]; I2 = 30.1%; z = 6.58;

p < 0.001

_

_

_

_

_

premenopausal vs. postmenopausal

0.963 [0.716,1.296];

I2 = 0.0%; z = 0.25;

p = 0.804

_

1.036 [0.629,1.708]; I2 = 29.3%; z = 0.14;

p = 0.888

0.874 [0.571,1.339]; z = 0.62;

p = 0.537

_

_

TNM stage: III, IV vs. I, II

0.825 [0.220,3.095]; I2 = 81.4%; z = 0.29;

p = 0.775

0.431 [0.211,0.881];

I2 = 0.0%; z = 2.31;

p = 0.021

1.268 [0.684,4.050]; I2 = 0.0%; z = 1.12;

p = 0.261

_

_

_